B. Riley initiated coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in a research note published on Tuesday, The Fly reports. The brokerage issued a buy rating and a $40.00 target price on the stock.
Other analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, December 19th. ValuEngine cut shares of Syndax Pharmaceuticals from a buy rating to a hold rating in a report on Monday, November 26th. Nomura reduced their target price on shares of Syndax Pharmaceuticals from $22.00 to $12.00 and set a buy rating for the company in a report on Tuesday, December 18th. Finally, Morgan Stanley cut shares of Syndax Pharmaceuticals from an overweight rating to an equal weight rating and set a $6.00 target price for the company. in a report on Monday, October 29th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Syndax Pharmaceuticals currently has an average rating of Buy and a consensus price target of $16.25.
Shares of SNDX stock opened at $6.53 on Tuesday. Syndax Pharmaceuticals has a 12 month low of $3.39 and a 12 month high of $15.20. The company has a market cap of $141.81 million, a price-to-earnings ratio of -2.25 and a beta of 2.14.
Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its position in shares of Syndax Pharmaceuticals by 5.2% in the third quarter. BlackRock Inc. now owns 1,757,844 shares of the company’s stock worth $14,202,000 after purchasing an additional 87,028 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Syndax Pharmaceuticals by 42.4% in the third quarter. Dimensional Fund Advisors LP now owns 795,767 shares of the company’s stock worth $6,428,000 after purchasing an additional 237,042 shares during the period. 683 Capital Management LLC boosted its position in shares of Syndax Pharmaceuticals by 32.4% in the second quarter. 683 Capital Management LLC now owns 375,000 shares of the company’s stock worth $2,633,000 after purchasing an additional 91,770 shares during the period. Renaissance Technologies LLC boosted its position in shares of Syndax Pharmaceuticals by 560.3% in the third quarter. Renaissance Technologies LLC now owns 279,300 shares of the company’s stock worth $2,257,000 after purchasing an additional 237,000 shares during the period. Finally, Morgan Stanley boosted its position in shares of Syndax Pharmaceuticals by 10.7% in the third quarter. Morgan Stanley now owns 269,595 shares of the company’s stock worth $2,178,000 after purchasing an additional 26,043 shares during the period. Institutional investors and hedge funds own 61.75% of the company’s stock.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Featured Story: Balanced Fund
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.